Loading clinical trials...
Loading clinical trials...
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Conditions
Locations
36
United States
City of Hope
Duarte, California, United States
Stanford Cancer Institute (Stanford University)
Stanford, California, United States
Boca Raton Regional Hospital, Lynn Cancer Institute, 701 NW 13th Street
Boca Raton, Florida, United States
University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Orlando Health
Orlando, Florida, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Start Date
December 1, 2015
Primary Completion Date
June 28, 2024
Completion Date
June 28, 2024
Last Updated
March 4, 2025
Lead Sponsor
Adaptimmune
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions